Ftse Mib
34.228,77
0,71%
DAX
18.430,05
1,42%
S&P 500
5.195,49
0,28%
NASDAQ
16.385,56
0,22%
Bitcoin
63.718,95
0,87%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ChromaDex Corporation (CDXC) ChromaDex Corporation (CDXC) Notizie

ChromaDex Corporation

CDXC
3,815
0,015 (0,39%)
Ultimo aggiornamento: 17:55:10
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202414:32BWChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR),..
25/4/202414:34BWChromaDex Announces Nationwide Launch of Tru Niagen® at The..
24/4/202414:34BWChromaDex to Report First Quarter 2024 Financial Results on..
23/4/202414:32BWChromaDex Announces Inaugural Major Grocery Debut of Tru..
26/3/202413:32BWChromaDex Announces Tru Niagen® is Now Third-Party Verified..
06/3/202422:04BWChromaDex Corporation Reports Fourth Quarter and Fiscal Year..
06/3/202422:02EDGAR2Form 8-K - Current report
06/3/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
24/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202402:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202414:32BWChromaDex to Report Fourth Quarter 2023 Financial Results on..
05/2/202414:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
26/1/202422:08BWChromaDex to Present at the Lytham Partners 2024 Investor..
20/12/202315:04BWChromaDex Supports the US Military with its Industry Leading..
13/12/202322:00EDGAR2Form 8-K - Current report
12/12/202316:30PRNUSNeurohacker Collective and ChromaDex Partner to Optimize..
04/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202314:34BWA Milestone Phase I Randomized, Double-Blind Clinical Trial..
15/11/202314:32BWNewly Published Phase II Clinical Study Demonstrates that..
09/11/202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
08/11/202322:02EDGAR2Form 8-K - Current report
08/11/202322:02BWChromaDex Corporation Reports Third Quarter 2023 Financial..
08/11/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:34BWChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg..
31/10/202313:34BWChromaDex to Report Third Quarter 2023 Financial Results on..
26/10/202314:32BWChromaDex and Zesty Paws® Crack the Code on Cellular Health..
02/10/202314:32BWA Milestone Clinical Study Reveals that Elevating..
07/9/202312:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202312:20EDGAR2Form SC 13D/A - General statement of acquisition of..
24/8/202314:32BWPreclinical Study Builds on Growing Body of Evidence..
16/8/202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:02EDGAR2Form 8-K - Current report
09/8/202322:02BWChromaDex Corporation Reports Second Quarter 2023 Financial..
09/8/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202314:34BWChromaDex Launches Tru Niagen® with iHerb, the World’s..
07/8/202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
02/8/202314:02BWChromaDex to Report Second Quarter 2023 Financial Results on..
18/7/202314:32BWFindings from Published Abstracts Showcase the Importance of..
06/7/202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/7/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
16/6/202314:32BWChromaDex, a Global Authority on Nicotinamide Adenine..
30/5/202314:34BWChromaDex to Participate in the LD Micro Invitational XIII
11/5/202314:34BWChromaDex to Present at the Lytham Partners Spring 2023..
10/5/202322:02BWChromaDex Corporation Reports First Quarter 2023 Financial..
Apertura: 3,85 Min: 3,79 Max: 3,89
Chiusura: 3,80

La tua Cronologia

NASDAQ
CDXC
ChromaDex
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network